Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...

Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...

Vertex has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past, it’s that there are many kinds of pain.

The biotech also has a burgeoning gene therapy portfolio and pipeline. Working with CRISPR Therapeutics, Vertex has hit the ground running with Casgevy, its gene therapy for blood disorders.

16.0% of Oncternal Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 11.2% of Oncternal ...